A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Blisibimod (A 623) Administration in Subjects With Systemic Lupus Erythematosus

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Blisibimod (A 623) Administration in Subjects With Systemic Lupus Erythematosus

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2017

At a glance

  • Drugs Blisibimod (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Registrational; Therapeutic Use
  • Acronyms CHABLIS-SC1
  • Sponsors Anthera Pharmaceuticals
  • Most Recent Events

    • 05 Nov 2017 According to an Anthera Pharmaceuticals media release, additional findings from this trial were presented at the American College of Rheumatology (ACR) Annual Meeting.
    • 01 Nov 2017 According to an Anthera Pharmaceuticals media release, subgroup data from this trial will be highlighted at the American Society of Nephrology (ASN) Annual Meeting 2017.
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top